The content on this site is intended for healthcare professionals only
Dr Rodrigo Motta Guerrero discusses his ecancermedicalscience journal article 'Targeting BRAF V600E in metastatic colorectal cancer: where are we today?'.
He outlines that BRAF V600E metastatic colorectal cancer patients are usually associated with poor prognosis resulting in poor overall survival which is why they decided to conduct a review into the treatment options currently available.
Dr Guerrero explains the key findings of this review showed immunotherapy, the combination of BRAF and EGFR inhibitors and the combination of chemotherapy with angiogenic inhibitors have managed to prolong the survival of this patient population.
He concludes by highlighting how these review results might impact future research into metastatic colorectal cancer with BRAF V600E mutations.
Read the full study here
ASCO GU 2026: Updates in metastatic prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
Lung cancer screening and treatment in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Choosing wisely in multiple myeloma
